Divalproex Sodium Tablet, Delayed Release
Product Images NDC 0904-6860

7 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 0904-6860). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Spl-divalproex-structure (Spl Divalproex Structure)
Chemical structure diagram of divalproex sodium showing its molecular arrangement with sodium ion and organic groups. The image illustrates the repeating unit of divalproex sodium polymer.*
FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)
A bar chart titled "Figure 1" showing percentage comparisons in two studies: Study 1 (YMRS) and Study 2 (MRS). Each study compares placebo (PBO) and Divalproex Sodium (DVPX) with DVPX bars showing higher percentages (60% and 58%) than placebo (26% and 29%). Percentage values are labeled above each bar.*
FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)
A cumulative distribution plot showing the percentage reduction in CPS rate among patients treated with Divalproex Sodium (DVPX) compared to placebo. The graph depicts improvement, no change, or worsening of symptoms against the percentage of patients, illustrating the drug's effect versus placebo.*
FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)
A chart titled 'Figure 3' showing percent reduction in CPS rate on the vertical axis versus percent of patients on the horizontal axis. It compares improvement or worsening in CPS rate between high dose and low dose groups of Divalproex Sodium, with lines representing each dose group.*
FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)
A bar graph titled 'Figure 4 Mean 4-week Migraine Rates' showing comparative migraine rates for Placebo and Divalproex Sodium (DVPX) across two studies. The y-axis measures migraine rates from 0 to 6, with Placebo bars higher than DVPX bars in both Study 1 and Study 2, indicating lower migraine rates with Divalproex Sodium treatment in the studies.*
FDA Label Image

250mg Carton Label (9fa8a32e 7def 4ae6 B537 15450ef34bc2 01)

250mg Carton Label (9fa8a32e 7def 4ae6 B537 15450ef34bc2 01)
Divalproex Sodium Delayed-Release tablets, USP, 250 mg strength, in unit dose packaging by Major Pharmaceuticals. The label shows NDC 0904-6860-61 and indicates the package contains 100 tablets (10 x 10). It includes medication guide instructions, storage conditions, and dispensing information specifying institutional use only. Barcode and manufacturer details are also visible.*
FDA Label Image

500mg Carton Label (9fa8a32e 7def 4ae6 B537 15450ef34bc2 00)

500mg Carton Label (9fa8a32e 7def 4ae6 B537 15450ef34bc2 00)
Label for Major Pharmaceuticals Divalproex Sodium Delayed-Release Tablets, USP, 500 mg strength. The label indicates a unit dose package containing 100 tablets (10 x 10). It provides valproic acid activity and dosage instructions, cautions for pharmacists, storage guidelines, and a barcode. The label also notes prescription-only status and distribution details from Major Pharmaceuticals in Indianapolis, IN.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.